1145 related articles for article (PubMed ID: 9408699)
21. Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.
Lianghui G; Shusen Z; Tingbo L; Yan S; Weilling W; Anwei L
Transplant Proc; 2004 Jun; 36(5):1502-5. PubMed ID: 15251371
[TBL] [Abstract][Full Text] [Related]
22. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
23. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
24. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.
Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD
Nephrol Dial Transplant; 1993; 8(9):858-62. PubMed ID: 8255520
[TBL] [Abstract][Full Text] [Related]
25. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
26. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
27. A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Vanrenterghem Y
J Antimicrob Chemother; 2005 Mar; 55(3):391-4. PubMed ID: 15705636
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
31. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
[TBL] [Abstract][Full Text] [Related]
33. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
[TBL] [Abstract][Full Text] [Related]
34. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
Goral S; Ynares C; Dummer S; Helderman JH
Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
36. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
37. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy.
Mandanas RA; Saez RA; Selby GB; Confer DL
Am J Hematol; 1996 Feb; 51(2):104-11. PubMed ID: 8579049
[TBL] [Abstract][Full Text] [Related]
39. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
[TBL] [Abstract][Full Text] [Related]
40. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
